The Oncotype MAP test, previously known as PCDx, is a rapid, comprehensive tumor profiling panel that aids therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer. With minimal tissue requirements, the Oncotype MAP test utilizes next generation sequencing (NGS) and immunohistochemistry (IHC) to provide in-depth insights into genomic alterations in hundreds of cancer-related genes, including tumor mutations, copy number variants, fusions, tumor mutation burden (TMB), microsatellite instability, and protein expression.
Solid Tumor
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), MET (MET proto-oncogene, receptor tyrosine kinase)
See More ...
Next-Generation Sequencing (NGS) / Immunohistochemistry (IHC)